W&H Joins OSAP as a New 2024 Super Sponsor
W&H is proud to announce its support of the Organization for Safety, Asepsis and Prevention (OSAP) by becoming a Super Sponsor for 2024
W&H AIMS Workflow Microsite
Several years ago W&H developed a comprehensive and interactive microsite for Advanced Infection Prevention Management Solutions (AIMS) as a valuable resource for the dental professional community. This workflow offers key steps to successful infection prevention, correct reprocessing and hygiene management. The microsite is continuously updated with the latest findings and key information.
W&H's Lexa & Lexa Plus Sterilizers Recent Recognition
Both of W&H's sterilizers offer a unique feature of using fresh water for every cycle (never recycled water) and closed-door drying which are critical in effective infection prevention. They also both offer high capacity, and fast cycle times for maximum efficiency.
- The Lexa sterilizer was recently awarded a 2024 Preferred Product in the sterilizer category by Dental Advisor for its outstanding performance and 4.5 star rating by its clinical evaluators.
- The Lexa Plus sterilizer was recently selected by Dental Products Report as their Top 5 Infection Control Products for 2023 and is the only sterilizer selected for this category.
"We are very excited to become a Super Sponsor in support of OSAP, given our strong reputation in the dental industry for our passion in educating the dental community on the critical importance of proper sterilization and vigorous focus on continued innovation," says
About W&H
W&H Impex, Inc. located in
View original content to download multimedia:https://www.prnewswire.com/news-releases/wh-joins-osap-as-a-new-2024-super-sponsor-302051082.html
SOURCE W&H Impex Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
- Hisense Unveils 2026 E8S ULED MiniLED TV Models with Exclusive Amazon Launch Deals
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share